Aliases:This biomarker is also known as:
- Secreted phosphoprotein 1,
- early T-lymphocyte activation 1,
- Bone sialoprotein 1,
- Urinary stone protein,
Osteopontin, also known as SPP1 or OPN, a secreted, integrin-binding matrix phosphorylated glycoprotein is involved in bone remodeling by osteoclasts and is overexpressed in many advanced cancers. Osteopontin has been identified as one of the leading genes that promotes the metastasis of hepatocellular carcinoma.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
No additional data available.
Ninety biomarkers were measured using a series of multiplexed immunoassays and results analyzed by the EDRN data management center splitting the cases and controls into training and validation sets, excluding subjects with DCIS or atypical hyperplasia from the training phase. We found little evidence that any of these markers can discriminate women with invasive cancer from those with benign breast conditions.
|QA State:||Under Review|
Osteopontin and other small integrin-binding ligand N-linked glycoproteins are emerging as important players in many stages of cancer progression. Chosen for the EDRN by detection in microarray expression studies.
It has been shown that serum osteopontin levels can be used to discriminate between persons with exposure to asbestos who do not have early pleural mesothelioma and those with exposure to asbestos who do have early pleural mesothelioma, regardless of the histologic type of the mesothelioma. (Pass et. al., 2005, PMID:16221779)
|QA State:||Under Review|
Osteopontin (OPN) is a secreted, integrin-binding matrix phosphorylated glycoprotein that is overexpressed in many advanced cancers. The expression of OPN by HO-8910 ovarian cancer cells greatly promoted the progression of ovarian cancer. OPN expression dramatically increased the colony formation of ovarian cancer cells in vitro and tumor growth in vivo. Under the stress induced by serum depletion or curcumin treatment, OPN expression promoted the survival of ovarian cells through preventing stress-induced apoptosis. At the molecular level, both endogenous and exogenous OPN expression activated the PI3-K/Akt survival pathway and dramatically decreased p53 expression under serum depletion. In addition, HIF-1alpha was induced in OPN-producing cells under normoxia. Furthermore, we also found that inhibition of the PI3-K/Akt pathway attenuated OPN-mediated HIF-1alpha up-regulation in ovarian cancer cells. Taken together, these results indicate that OPN can increase the survival of ovarian cancer cells under stress conditions in vitro and promote the late progression of ovarian cancer in vivo, and the survival-promoting functions of OPN are mediated through Akt activation and the induction of HIF-1alpha expression.
Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. Osteopontin (SPP1) alone was not a strong predictor.
- Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
- Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer.
- Cellular and molecular parameters of mesothelioma.
- Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma.
- Novel surface targets and serum biomarkers from the ovarian cancer vasculature.
- HGNC entry for SPP1 from Genenames
- KEGG entry for SPP1 from Genome.jp
- Entrez entry for SPP1 all NCBI Databasese
- Human GEO Profiles for SPP1 from NCBI GEO Profiles
- Human Geo Datasets containing term SPP1 from NCBI GEO Datasets
- GWAS Study Datasets containing gene SPP1 from GWAS
- Human Single Nucleotide Polymorphisms info for SPP1
- Human Gene(s) with 'SPP1' as Gene Name/Alias
- Human Gene RefSeq for SPP1 from NCBI
- GeneCards entry for human SPP1
- UniProtKB/Swiss-Prot entry for SPP1 from Uniprot
- Human Protein RefSeq for SPP1 from NCBI
- FDA web page describing approval of SPP1
|UniProt Accession #:||P10451|
|Mutated Sites Count:||167|
|Associated Pubmed ID Count||11|
|Affected Protein Function Sites Count:||4|